Can ruxolitinib stop a deadly transplant complication in kids?
NCT ID NCT06128070
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the drug ruxolitinib to the usual anti-rejection medicines (tacrolimus and methotrexate) can prevent graft-versus-host disease (GVHD) in children and young adults getting a stem cell transplant for leukemia or myelodysplastic syndrome. GVHD happens when donor cells attack the patient's body. The trial will enroll 40 people aged 2 to 22 and track side effects and how well the combo works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ruxolitinib
- What this could lead to
- If successful, adding ruxolitinib could become a new standard to prevent graft-versus-host disease, improving recovery and survival for young transplant patients.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Ruxolitinib can cause side effects like infections or blood cell changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?